Diabetes can silently damage the blood vessels in your retina for years before you notice anything wrong. Regular screening is not optional. Full stop. It is what stands between manageable disease and permanent vision loss.
Diabetic retinopathy is a complication of diabetes that affects the tiny blood vessels supplying the retina at the back of the eye. Over time, high blood sugar levels damage these vessels: they leak, swell, or grow abnormally, gradually disrupting the retina’s ability to function. It is the leading cause of preventable blindness in working-age adults in developed countries. By the time vision is affected, significant and often irreversible damage has already occurred. This is a condition where screening and early intervention make an enormous difference.
What You Need to Know About Diabetic Retinopathy
- Diabetic retinopathy affects around 1 in 3 people with diabetes and is present in the majority of those who have had diabetes for 20 years or more
- In the early stages it causes no symptoms at all. Vision loss is a late sign, which is why annual retinal screening matters so much
- Both type 1 and type 2 diabetes can cause retinopathy. Duration of diabetes and blood sugar control are the strongest risk factors
- Tight control of blood glucose, blood pressure, and blood lipids slows progression substantially
- Sight-threatening disease is highly treatable with anti-VEGF injections and laser, particularly when caught early
- Smoking worsens diabetic vascular disease throughout the body. Stopping protects your eyes as well as everything else
The Stages of Diabetic Retinopathy
Diabetic retinopathy progresses through well-defined stages. Knowing where you are helps make sense of what your ophthalmologist is monitoring and why the frequency of your appointments matters. Diabetic eye disease is closely related to glaucoma risk.
Mild non-proliferative DR (NPDR)
Tiny balloon-like swellings called microaneurysms appear in the walls of the retinal vessels. The earliest detectable sign. Vision is typically completely normal. Optimising blood glucose, blood pressure, and cholesterol is the main intervention at this stage, alongside annual monitoring.
Moderate non-proliferative DR
More vessels become damaged and begin to leak. Dot and blot hemorrhages appear on the retina alongside hard exudates (deposits of leaked lipids). Vision may still be normal unless the leakage affects the central macula. Monitoring becomes more frequent and systemic risk factor control more important.
Severe non-proliferative DR
Many more vessels are blocked, depriving areas of retina of their blood supply. The retina responds by sending signals for new vessel growth. High risk of progressing to proliferative disease within a year. Treatment is often initiated here and close monitoring is important.
Proliferative DR (PDR)
Abnormal new blood vessels grow on the retinal surface and into the vitreous. These fragile vessels bleed easily, causing sudden vision loss from vitreous hemorrhage. Scar tissue can pull on the retina, leading to tractional retinal detachment. PDR requires prompt treatment and is sight-threatening.
Diabetic Macular Edema
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic retinopathy and can occur at any stage, not just late disease. Damaged blood vessels leak fluid into the macula, the central area of the retina responsible for sharp detail vision. The fluid causes the macula to swell, blurring and distorting central vision. It is now highly treatable with anti-VEGF injections, and most patients who receive prompt treatment maintain or improve their vision.
Risk Factors and Prevention
Blood sugar control
Duration of diabetes and the level of blood glucose control over time are the two most powerful determinants of whether retinopathy develops and how quickly it progresses. Every reduction in HbA1c reduces the risk. Intensive glucose control in the early years of diabetes substantially reduces the lifetime risk of sight-threatening retinopathy, an effect that persists for years even if control later deteriorates. This is sometimes called the legacy effect, and it is one of the most compelling arguments for tight control from the start.
Blood pressure and cholesterol
High blood pressure accelerates retinal vessel damage independently of blood glucose levels. Tight blood pressure control reduces the risk of retinopathy progression by around a third. That number is worth sitting with. High cholesterol is associated with more hard exudate formation and macular involvement. Managing all three risk factors simultaneously gives the best protection.
Pregnancy
Pregnancy can cause rapid progression of diabetic retinopathy, particularly in women with pre-existing disease. Women with diabetes planning a pregnancy should have a retinal examination early and be monitored more frequently throughout. This is not a reason to avoid pregnancy, but it should be planned carefully with medical support.
Treatment
Anti-VEGF injections
Anti-VEGF medications injected into the vitreous cavity are the first-line treatment for DME and for proliferative retinopathy with active new vessel growth. They block the signal that drives both the leakage and abnormal vessel growth. Treatment typically involves a loading phase of monthly injections, then a maintenance schedule based on retinal response at each visit assessed with an OCT scan.
Laser treatment
Pan-retinal photocoagulation (PRP) laser applies burns to the peripheral retina, reducing the retina’s demand for oxygen and suppressing the stimulus for new vessel growth. PRP has largely been supplemented by anti-VEGF injections in many cases but remains important for patients who cannot attend regularly for injections or when injections alone are insufficient.
Vitreoretinal surgery
In advanced PDR complicated by non-clearing vitreous hemorrhage or tractional retinal detachment, vitreoretinal surgery may be needed. The surgeon removes the blood-filled vitreous and any fibrovascular scar tissue pulling on the retina. Outcomes depend heavily on how much retinal damage occurred before surgery. Getting to this point is precisely what the whole treatment pathway aims to prevent.
The Most Important Thing You Can Do: Attend Your Screening
Annual diabetic eye screening exists for one reason: to detect retinopathy before it causes symptoms, when treatment is most effective and vision loss most preventable. Diabetic retinopathy causes no pain and no noticeable vision change in its early and treatable stages. By the time something feels wrong, the opportunity for the simplest intervention has often passed.
Missing screening appointments is one of the most significant risk factors for preventable blindness from diabetic retinopathy. If you have diabetes and haven’t had a retinal photograph in the past year, booking one now is the single most important action you can take for your eyesight. If you were referred for hospital review and haven’t yet attended, please don’t delay further.
Screening is not the same as a standard optician’s check. It specifically photographs the retina to detect early signs that cannot be seen without dilating the pupil and examining the back of the eye in detail.
Seek Urgent Eye Care the Same Day If You Notice
- A sudden increase in floaters or new dark spots in your vision
- A dark curtain, shadow, or veil appearing across part of your visual field
- A sudden significant loss of vision in one eye
- Vision that has become noticeably and rapidly worse over hours or days
These symptoms can indicate vitreous hemorrhage or retinal detachment, both serious complications of proliferative diabetic retinopathy. Don’t wait to see if they improve. Contact your eye unit or an emergency eye service the same day.
Frequently Asked Questions About Diabetic Retinopathy
-
My vision is fine. Do I still need eye screening?
Absolutely. This is the single most important message in diabetic eye care. Diabetic retinopathy can be at a moderately advanced stage and still cause no noticeable change in vision. The damage accumulates silently. Annual screening catches it at the stage when treatment is simplest and outcomes are best.
-
My diabetes is well controlled. Can I still get retinopathy?
Yes, though good control substantially reduces the risk and slows progression. Duration of diabetes matters alongside control: someone who has had well-controlled diabetes for 25 years still has a meaningful cumulative risk. Good control is absolutely the right goal, but it doesn’t eliminate the need for annual retinal screening. Both are necessary.
-
Will I go blind from diabetic retinopathy?
Most people with diabetic retinopathy don’t go blind. That’s worth saying clearly, because a lot of newly diagnosed patients assume the worst. Regular screening and appropriate treatment when needed make the difference. Modern treatments for DME and proliferative retinopathy are highly effective when started at the right time. The patients at greatest risk of blindness are those who don’t attend screening, present late with advanced disease, or have poor systemic risk factor control over many years.
-
Are the injections painful?
For patients who need injections long-term — and many people with diabetic retinopathy do — the procedure quickly becomes just another part of the schedule. The eye is numbed beforehand, the injection takes a few seconds, and most people feel nothing beyond mild pressure. The first one is almost always the most daunting. By the third or fourth, most patients barely give it a second thought. The grittiness that follows for a day or two, and the red patch on the white of the eye that looks much worse than it is, are entirely normal and temporary.
-
How often do I need injections?
Treatment schedules vary depending on how the retina responds. Most patients start with monthly injections for a loading phase, then move to a schedule adjusted at each visit based on the OCT findings. Some achieve stable disease and can extend intervals considerably. Others need ongoing treatment for years. Missing appointments risks fluid returning and vision declining, so consistent attendance matters even when the eye feels comfortable. Specialist care is provided by the retina team.
-
Can improving my blood sugar reverse retinopathy?
In the very early stages, better glucose control can slow or stabilize mild retinopathy. Established retinal damage cannot be reversed by control alone. One genuinely counterintuitive point: a very rapid improvement in blood glucose can temporarily worsen retinopathy before it stabilizes. That shouldn’t discourage better control, but it does mean such transitions should be monitored closely by your eye team.
If you would like to learn more, the American Academy of Ophthalmology’s diabetic retinopathy page offers a clear overview of causes, symptoms, treatment, and how diabetes can affect the retina and threaten vision.
Diabetic retinopathy (DR) is the most common cause of new sight loss in working-age adults in high-income countries and affects approximately one third of people with diabetes globally. It is a microangiopathy driven by chronic hyperglycemia, acting primarily on retinal capillary endothelial cells and pericytes. The consequences range from microaneurysm formation through to neovascularization and tractional retinal detachment (TRD). Diabetic macular edema (DME) is the most frequent cause of vision loss in DR and can occur at any stage. Management is primarily through systemic glycemic and vascular risk factor control, with intravitreal therapy and laser the cornerstones of sight-threatening disease treatment. The UKPDS and DCCT trials demonstrated definitively that tight glycemic control reduces the incidence and progression of DR. Neovascular complications parallel those seen in retinal vein occlusion by 25-76% depending on diabetes type.
Clinical Overview: Diabetic Retinopathy
- Classification (ETDRS/International): Non-proliferative DR (NPDR) , mild, moderate, severe (the 4-2-1 rule); Proliferative DR (PDR) , new vessels at disc (NVD) or elsewhere (NVE), with or without vitreous hemorrhage (VH) or TRD
- 4-2-1 rule for severe NPDR: Any one of: hemorrhages in all 4 quadrants, venous beading in 2+ quadrants, IRMA in 1+ quadrant. 50% chance of developing PDR within 1 year.
- DME diagnosis: Center-involving DME (CI-DME) on OCT , subretinal or intraretinal fluid within 1 disc diameter of the fovea with central subfield thickness typically above 300 µm. Non-CI-DME is managed differently.
- First-line DME treatment: Intravitreal anti-VEGF (PROTOCOL T: aflibercept, ranibizumab, bevacizumab all effective; aflibercept shows superior initial gains in BCVA below 69 letters). Intravitreal dexamethasone implant (Ozurdex) for anti-VEGF non-responders or pseudophakic patients
- PDR treatment: Pan-retinal photocoagulation (PRP) remains standard; anti-VEGF (aflibercept) shown non-inferior to PRP at 2 years in CLARITY trial with lower rates of DME and VF loss
- Systemic targets: HbA1c below 7% (53 mmol/mol), BP below 130/80, statin therapy, ACE inhibitor/ARB for nephropathy
Pathophysiology
Chronic hyperglycemia triggers several parallel pathways: activation of protein kinase C, advanced glycation end-product (AGE) accumulation, polyol pathway flux, and oxidative stress. Together these damage retinal pericytes (leading to microaneurysm formation and capillary non-perfusion), disrupt the inner blood-retinal barrier (leading to leakage and DME), and drive upregulation of VEGF by ischemic retinal tissue (the proximate driver of neovascularization). Pericyte loss is the earliest ultrastructural change, preceding clinically visible findings by years.
Neovascularization pathway: VEGF (vascular endothelial growth factor) is released by hypoxic retina in response to capillary non-perfusion. New vessels grow along the vitreoretinal interface (NVD or NVE), are structurally weak, and bleed into the vitreous (VH). Fibrovascular proliferation causes tractional retinal detachment if untreated. Anti-VEGF treatment directly addresses this driver.
Classification and Staging
ETDRS severity scale (simplified International Classification):
- No apparent DR: No lesions
- Mild NPDR: Microaneurysms only
- Moderate NPDR: More than mild but less than severe; dot/blot hemorrhages, hard exudates, soft exudates
- Severe NPDR: 4-2-1 rule , any one of: hemorrhages in all 4 quadrants, venous beading in 2+ quadrants, intraretinal microvascular abnormalities (IRMA) in 1+ quadrant. No neovascularization.
- PDR: Neovascularization (NVD or NVE), with or without VH or TRD
- High-risk PDR: NVD greater than one quarter disc area, or any NVD with VH, or NVE with VH
DME is classified separately. Center-involving DME (CI-DME) threatens the fovea and requires prompt treatment. Non-center-involving DME may be observed with close monitoring. OCT central subfield thickness (CST) above 300 µm in CI-DME is a common treatment threshold, though the specific value varies by scanner and protocol.
Investigation
OCT: Mandatory for DME diagnosis and treatment monitoring. Identifies subretinal fluid (SRF), intraretinal fluid (IRF), disorganization of retinal inner layers (DRIL, a predictor of poor visual recovery), and epiretinal membrane contributing to edema. CST reduction and DRIL resolution are key treatment response markers.
Wide-field fundus photography and FA: Documents the distribution of capillary non-perfusion (which predicts neovascularization risk and limits visual potential). Wide-field FA reveals peripheral ischemia not seen on standard 7-field photography. OCT-A increasingly supplements FA for non-invasive mapping of the foveal avascular zone (FAZ) enlargement and capillary loss.
Management: DME
Intravitreal anti-VEGF, first-line CI-DME: PROTOCOL T (2015) compared aflibercept 2 mg, ranibizumab 0.3 mg, and bevacizumab 1.25 mg at 1 and 2 years. All three produced significant BCVA gains. Aflibercept showed superior gains in eyes with initial BCVA 20/50 or worse (approximately +19 vs +12 ETDRS letters at 1 year) , the difference narrowed at 2 years. Faricimab (Vabysmo) demonstrated non-inferiority to aflibercept with extended dosing intervals up to 16 weeks (YOSEMITE/RHINE trials).
Intravitreal dexamethasone implant (Ozurdex): 0.7 mg biodegradable implant, active for approximately 4-6 months. Preferred in pseudophakic eyes (avoids significant lens change seen in phakic eyes), anti-VEGF non-responders, and patients in whom injection frequency is a major concern. IOP monitoring required. MEAD trial: sustained CST reduction and +3.5 letter gain vs sham at 3 years.
Focal/grid laser: The historical standard (ETDRS protocol). Now reserved for non-CI-DME with discrete leaking microaneurysms, or as adjunct to reduce anti-VEGF injection frequency in specific cases. Not appropriate for CI-DME where the fovea is at risk.
Management: PDR
Pan-retinal photocoagulation (PRP): The ETDRS-proven standard for high-risk PDR. Destroys ischemic peripheral retina to reduce VEGF drive. Causes peripheral VF loss, color vision changes, and night vision impairment , limitations that matter increasingly with younger patients and active drivers. Delivered in 2-4 sessions. Regression of NVD/NVE expected within 3-6 months.
Intravitreal aflibercept for PDR: CLARITY trial (2017): aflibercept 2 mg non-inferior to PRP at 1 year for BCVA, with significantly lower rates of DME (5% vs 28%) and VF loss. Two-year data showed durability. Practical limitation: patients must attend for frequent injections; missed injections risk rebound neovascularization. PDR treatment with anti-VEGF requires reliable follow-up , PRP is still preferred when follow-up is uncertain.
Vitrectomy: Indicated for non-clearing VH (after 3-4 months or earlier in T1DM), TRD threatening or involving the macula, combined TRD/RRD, and severe fibrovascular proliferation not responsive to laser/anti-VEGF. Pre-operative intravitreal anti-VEGF (48-72 hours before) reduces intraoperative bleeding and facilitates membrane peeling.
Systemic Co-management
Glycemic control: DCCT: every 10 mmol/mol reduction in HbA1c reduces DR progression risk by approximately 40% in T1DM. UKPDS: similar reduction in T2DM. Intensive control in the first 10 years of T1DM produces lasting “metabolic memory” effects. Be aware: rapid improvement in HbA1c can paradoxically worsen DR in the short term (early worsening phenomenon) , warn patients with moderate-severe NPDR before initiating intensive glycemic therapy.
Blood pressure control below 130/80 mmHg reduces DR progression. RAAS inhibition (ACE inhibitors, ARBs) has independent retino-protective effects beyond BP lowering in T2DM. Lipid-lowering with fenofibrate reduces the need for laser treatment in moderate NPDR (FIELD trial: 31% reduction in laser procedures). Referral to the diabetologist is part of the ophthalmologist’s job. Patients with DR and concurrent glaucoma (elevated IOP from steroid injections or neovascular glaucoma) require coordinated management. is part of the ophthalmologist’s job, not an afterthought.
Clinical Decision Points
- Severe NPDR, HbA1c poorly controlled, unreliable follow-up: Consider PRP rather than observation alone. The 50% 1-year PDR conversion risk is not acceptable if follow-up is uncertain.
- PDR + CI-DME: PRP can worsen DME acutely by increasing VEGF leakage from laser-induced inflammation. Anti-VEGF for the DME first, then reassess for PRP, or treat both simultaneously with anti-VEGF covering both conditions.
- Anti-VEGF non-response (DME): After 6 monthly injections with less than 10% CST reduction or less than 5-letter BCVA gain: switch agent, add dexamethasone implant, or investigate alternative causes (epiretinal membrane, subretinal fluid organization, chronic structural change on OCT).
- Pregnancy and DR: Pregnancy accelerates DR progression, particularly in T1DM with existing moderate/severe NPDR. Pre-conception counseling and DR examination each trimester are mandatory. Anti-VEGF is not used in pregnancy; laser may be needed.
Same-Day Assessment Required
- Sudden vision loss or new dense floaters in a known PDR or severe NPDR patient , exclude vitreous hemorrhage (B-scan ultrasound if fundus not visible) or TRD
- New tractional retinal detachment on examination threatening or involving the macula , refer vitreoretinal surgery same day
- Rubeosis iridis (new vessels at the iris or angle) , indicates severe ischemic drive; requires urgent PRP and IOP management
Neovascular glaucoma secondary to rubeosis: intravitreal anti-VEGF causes rapid regression of iris vessels and buys time for PRP. IOP lowering (topical and/or systemic) concurrently. This is a sight-threatening emergency.
Clinical Pearls: Diabetic Retinopathy
-
Rapid HbA1c reduction can transiently worsen DR. Always warn patients before intensive therapy.
The early worsening phenomenon is well documented: reducing HbA1c from above 10% to below 7% over weeks to months can trigger cotton-wool spots and IRMA formation. The mechanism involves altered retinal blood flow autoregulation. The long-term benefit of control still outweighs this risk, but patients with moderate or severe NPDR should be photographed at the time of systemic intensification and reviewed at 3 months rather than 12.
-
DRIL on OCT predicts final visual acuity better than central subfield thickness alone.
Disorganization of retinal inner layers reflects inner retinal ischemia and structural damage that anti-VEGF cannot reverse. When DRIL spans more than half the central 1 mm zone, the visual prognosis is guarded regardless of fluid resolution. Communicating this to patients early avoids unrealistic expectations and guides treatment intensity decisions , aggressive injection regimens in eyes with extensive DRIL provide limited functional return.
-
Fenofibrate is underused in type 2 diabetes with moderate NPDR. It is not a lipid agent in this context.
Fenofibrate’s retinal protective effects in DR appear independent of its lipid-lowering action (FIELD and ACCORD Eye trials). The mechanism is thought to involve PPAR-alpha activation and anti-inflammatory effects on the retinal vasculature. For T2DM patients with moderate NPDR on regular eye clinic follow-up, a conversation with the diabetologist about fenofibrate is worth having , it reduced first laser treatment by 31% in FIELD at 5 years.
-
Bilateral simultaneous intravitreal anti-VEGF injections for DME are safe and efficient. Sequential bilateral injections are not standard without good reason.
Bilateral DR with bilateral CI-DME is common. Bilateral same-day injections (BSDI) reduce visit burden and are supported by safety data showing no increased endophthalmitis risk when separate equipment and separate consent are used. Many centres still treat sequentially out of historical caution rather than current evidence. Discuss the option with patients where follow-up adherence is a practical concern.
Further reading: AAO Preferred Practice Pattern , Diabetic Retinopathy. For the diabetic eye in the broader context of systemic risk, see the retina subspecialty page and retinal vein occlusion, which shares the anti-VEGF management standard.